Market Chatter: Tesla Pressures European Regulators Over Full Self-Driving Approval
MT newswire2026/10/07 08:5404:54 AM EDT, 10/07/2026 (MT Newswires) -- Tesla (TSLA) is pushing European regulators to speed approval of its Full Self-Driving technology, using social media and safety research to build support for the driver-assistance system, Reuters reported Wednesday. According to the report, the company has won approval in the Netherlands and seven other EU countries, paving the way for an EU-wide vote. However, traffic-safety researchers who reviewed Tesla's European safety research for Reuters said the data does not support the company's claim that FSD prevents fatal crashes, the report said. Tesla has urged regulators to scale back safety reviews, using social media to encourage supporters to lobby European officials for faster approvals, Reuters added. Tesla did not immediately respond to MT Newswires' request for comment. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Kalshi Submits Proposal for Perpetual Oil Contracts to the CFTC
Google partners with Unity (U.US) to develop a next-generation gaming platform: Create games by simply speaking, no coding required
Google has formed a strategic partnership with Unity, planning to launch an integrated gaming platform within the year that allows for creation with natural language. Unity shares rose nearly 6% in pre-market trading, while Roblox dropped nearly 5%.
BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises
On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.
Crypto prices
More
